Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5585273 | Bone | 2017 | 25 Pages |
Abstract
In postmenopausal Japanese women with osteoporosis, romosozumab treatment resulted in large and significant gains in BMD from baseline and compared with placebo. Romosozumab 210Â mg QM showed the largest gains in BMD and was generally well tolerated. The efficacy and safety of romosozumab 210Â mg QM in this phase 2 study of postmenopausal women with osteoporosis were similar to those in an international phase 2 study.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Hideaki Ishibashi, Daria B. Crittenden, Akimitsu Miyauchi, Cesar Libanati, Judy Maddox, Michelle Fan, Li Chen, Andreas Grauer,